PTAB shoots down tenth I-MAK Gilead challenge

24-07-2018

PTAB shoots down tenth I-MAK Gilead challenge

tumsasedgars / iStockphoto.com

The Patent Trial and Appeal Board (PTAB) has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.


Initiative for Medicines, Access & Knowledge, I-MAK, patent, Sovaldi, Gilead, generics, hepatitis C, pharmaceuticals, PTAB

LSIPR